Publications.
Presentations.
Posters.
Explore related scientific papers by our founders, along with Teitur posters and presentations showcasing our efforts in developing new therapies for degenerative diseases.
Publications.
September 18, 2025
A low frequency damaging SORCS2 variant identified in a family with ADHD compromises receptor stability and quenches activity
September 17, 2025
The SorCS2-derived macrocycle TT-P34 drives neuroprotection in animal models of neurodegeneration (preprint)
June 20, 2025
A triple serine motif in the intracellular domain of SorCS2 impacts its cellular signaling
September 9, 2023
Alternative splicing regulates adaptor protein binding, trafficking, and activity of the Vps10p domain receptor SorCS2 in neuronal development
May 17, 2019
Reduced Alcohol Seeking and Withdrawal Symptoms in Mice Lacking the BDNF Receptor SorCS2
June 26, 2016
SorCS2 is required for BDNF-dependent plasticity in the hippocampus
Presentations.
April 5, 2025
TT-P34: a first-in-class peptide drug for treatment of neurodegeneration (ADPD)
Posters.
February 24, 2025
TT-P34: A novel first-in-class peptide drug for Huntington's Disease (HDTC)
March 9, 2024